Brief: Prelude Therapeutics Announces Collaboration With Merck For PRT3789 In Combination With Keytruda In SMARCA4-Mutated Cancers
09/07/2024 12:40
July 9 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH
MERCK
TO EVALUATE PRT3789 IN COMBINATION WITH KEYTRUDA®
(PEMBROLIZUMAB) IN PATIENTS WITH SMARCA4-MUTATED CANCERS
* PRELUDE THERAPEUTICS INC - PRELUDE WILL SPONSOR CLINICAL
TRIAL
AND MERCK WILL PROVIDE KEYTRUDA.
* PRELUDE THERAPEUTICS INC - EXPECTS TO CONCLUDE MONOTHERAPY
DOSE
ESCALATION MID-2024 AND IDENTIFY RECOMMENDED PHASE 2 DOSE
* PRELUDE THERAPEUTICS- CO, MERCK EACH RETAIN ALL COMMERCIAL
RIGHTS TO THEIR RESPECTIVE COMPOUNDS, INCLUDING AS MONOTHERAPY
OR AS COMBINATION THERAPIES
Source text for Eikon: ID:nGNX6Mr826
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview